Bioengineer Gang Bao uses gene editing to repair up to 40 percent of bone marrow cells from patients
Scientists have successfully used gene editing to repair 20 to 40 percent of stem and progenitor cells taken from the peripheral blood of patients with sickle cell disease, according to Rice University bioengineer Gang Bao.
Bao, in collaboration with Baylor College of Medicine, Texas Children’s Hospital and Stanford University, is working to find a cure for the hereditary disease. A single DNA mutation causes the body to make sticky, crescent-shaped red blood cells that contain abnormal hemoglobin and can block blood flow in limbs and organs.
In his talk at the annual American Association for the Advancement of Science meeting in Austin Feb. 16, Bao revealed results from a series of tests to see whether CRISPR/Cas9-based editing can fix the mutation. His presentation was part of a scientific session titled “Gene Editing and Human Identity: Promising Advances and Ethical Challenges.”
“Sickle cell disease is caused by a single mutation in the beta-globin gene (in the stem cell’s DNA),” he said. “The idea is to correct that particular mutation, and then stem cells that have the correction would differentiate into normal blood cells, including red blood cells. Those will then be healthy blood cells.”
Bao’s lab collaborated with Vivien Sheehan, an assistant professor of pediatrics and hematology at Baylor and a member of the sickle cell program at Texas Children’s, to collect stem and progenitor cells (CD34-positive cells) from patients with the disease. These were then edited in the Bao lab with CRISPR/Cas9 together with a custom template, a piece of DNA designed to correct the mutation.
The gene-edited cells were injected into the bone marrow of immunodeficient mice and tested after 19 weeks to see how many retained the edit. “The rate of repair remained stable, which is great,” Bao said. This engraftment study was carried out in the lab of Matt Porteus, an associate professor of pediatrics at Stanford.
Another major finding of the study is that the CRISPR/Cas9 system could introduce large alterations to the genes in patients’ cells, in addition to small mutations or deletions. These off-target effects could cause a disease.
The findings, part of an upcoming paper, are a step toward treating sickle cell disease. Obstacles in the way of a cure include optimizing the CRISPR/Cas9 system to eliminate off-target effects, as well as finding a way to further increase the amount of gene-corrected stem cells.
Bao pointed out that researchers still don’t know whether repairing as much as 40 percent of the cells is enough to cure a patient. “We’d like to say, ‘Yes,’” he said, “but we don’t really know yet. That’s something we hope to learn from an eventual clinical trial.”
Learn more: Rice U. reports progress in pursuit of sickle cell cure
The Latest on: Sickle cell disease
[google_news title=”” keyword=”Sickle cell disease” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Sickle cell disease
- Connecticut students with sickle cell disease embark on visit to NASA’s Goddard Space Centeron March 28, 2024 at 4:12 am
A group of Connecticut students with sickle cell disease are about to embark on a special trip that could pave the way to incredible careers in the future.
- Which drugs are most likely to be approved in Sickle Cell Disease With Vaso-Occlusive Crisis?on March 27, 2024 at 10:53 am
Sickle Cell Disease With Vaso-Occlusive Crisis disease is an indication for drug development with over 9 pipeline drugs currently active according to GlobalData.
- Pfizer Terminates Phase III Sickle Cell Study Due to Slow Patient Recruitmenton March 27, 2024 at 4:29 am
While Pfizer has ended one of its two Phase III studies for inclacumab in sickle cell disease, the company is still eyeing an approval for the antibody in the inherited blood disorder by 2026.
- After terminating one of 2 late-stage sickle cell disease trials, Pfizer still expects FDA approval in 2026on March 26, 2024 at 2:31 pm
The termination doesn’t impact Pfizer's plans for a potential new drug approval from the FDA in 2026, the company spokesperson said. Inclacumab has received both orphan and rare pediatric disease tags ...
- How subpar treatment options allow sickle cell disease to persist | Explainedon March 26, 2024 at 11:30 am
Access to healthcare for sickle cell disease in India, including gene-editing technology, raises equity and access concerns.
- Helping Patients Access Sickle Cell Disease Treatments In West Africaon March 24, 2024 at 2:53 pm
A researcher from Cameroon, working on sickle cell disease, is now aiming to help patients in low-income countries in west Africa afford the medicine that they need.
- Opinion: The revolutionary sickle cell therapieson March 21, 2024 at 9:28 am
In December, the FDA approved the first two cell-based gene therapies for treating sickle cell disease: Casgevy and Lyfgenia. And, like any emerging medical technology, the initial use of the ...
- Opinion: The revolutionary sickle cell therapieson March 21, 2024 at 9:28 am
Having two innovative therapies to treat a disease that affects a chronically ... director of the Sickle Cell Center at Cincinnati Children’s, says the CRISPR gene editing approach used ...
- New way for states to cover pricey gene therapies will start with sickle cell diseaseon March 20, 2024 at 9:40 am
The U.S. Food and Drug Administration late last year approved two breakthrough gene therapies for sickle cell disease patients. Now a new federal program seeks to make these life-changing treatments ...
- Highest Cost Sickle Cell Patients Spend an Average of Nearly $200,000 a Year on Medicaidon March 19, 2024 at 9:29 am
Sickle cell disease (SDC) is a group of inherited, debilitating blood disorders that commonly lead to frequent infections, bone fractures and often premature death. The condition changes the shape of ...
via Bing News